Overview
Tuberculosis of the epididymis, also known as epididymo-orchitis, is a localized manifestation of extrapulmonary tuberculosis primarily affecting the male genital tract. This condition is clinically significant due to its potential to cause significant morbidity, including infertility, if not promptly diagnosed and treated. It predominantly affects immunocompromised individuals, including those with HIV/AIDS, as well as individuals from regions with high tuberculosis prevalence. Early recognition and intervention are crucial in day-to-day practice to prevent irreversible damage to the epididymis and preserve reproductive function 12.Pathophysiology
The pathophysiology of tuberculosis affecting the epididymis involves the hematogenous spread of Mycobacterium tuberculosis to the male genital tract. Once the bacilli reach the epididymis, they are typically engulfed by resident macrophages and epithelial cells, particularly in the caput region where immune surveillance is robust. However, the unique microenvironment and immune responses within different regions of the epididymis—caput, corpus, and cauda—can influence the progression and manifestation of the disease. The caput region, with its specialized epithelial cells and higher immune activity, may initially contain the infection, but failure of containment can lead to spread to the corpus and cauda regions 1. The regional differences in epithelial cell types and their functional specialization, as highlighted by transcriptional profiling studies, suggest that the specific cellular responses and immune interactions vary along the length of the epididymis, potentially affecting disease progression and clinical presentation 1. Additionally, hormonal influences, such as estrogen receptor (ER) localization patterns, may modulate the inflammatory response and tissue damage, though the exact mechanisms in tuberculosis remain less explored 2.Epidemiology
The incidence of epididymal tuberculosis is relatively rare compared to other forms of extrapulmonary tuberculosis but is notable in endemic areas and among immunocompromised populations. Prevalence rates can vary widely depending on geographic location and public health measures. For instance, regions with high tuberculosis burden often report higher incidences, particularly among males aged 20-40 years, who are typically at higher risk due to occupational exposures or underlying health conditions 12. Trends over time suggest a decline in incidence with improved diagnostic capabilities and tuberculosis control programs, though sporadic outbreaks can still occur, especially in settings with suboptimal healthcare infrastructure 1.Clinical Presentation
Patients with epididymal tuberculosis often present with unilateral testicular swelling, pain, and tenderness. Common symptoms include fever, night sweats, and weight loss, reflecting systemic involvement. Atypical presentations may include vague lower abdominal discomfort or scrotal heaviness without overt swelling. Red-flag features include rapidly enlarging scrotal mass, associated systemic symptoms like significant weight loss, and signs of advanced infection such as abscess formation or fistula development. Early recognition of these symptoms is crucial for timely intervention to prevent complications like infertility 12.Diagnosis
The diagnosis of epididymal tuberculosis involves a combination of clinical assessment, laboratory tests, and imaging studies, often requiring a high index of suspicion due to its rarity and nonspecific symptoms. Key diagnostic steps include:Clinical Evaluation: Detailed history and physical examination focusing on scrotal swelling, associated systemic symptoms, and risk factors.
Laboratory Tests:
- Tuberculin Skin Test (TST) or Interferon-Gamma Release Assays (IGRAs): To assess latent tuberculosis infection.
- Complete Blood Count (CBC): Elevated white blood cell count may indicate infection.
- Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Elevated levels suggest ongoing inflammation.
Imaging:
- Ultrasonography: Can reveal hypoechoic lesions or hydrocele suggestive of epididymal involvement.
- MRI: Provides detailed imaging to differentiate from other causes of scrotal pathology.
Histopathology and Microbiology:
- Biopsy: Core needle biopsy or fine-needle aspiration from the affected epididymis.
- Microbiological Examination: Acid-fast bacilli (AFB) staining and culture of biopsy samples; nucleic acid amplification tests (NAATs) like Xpert MTB/RIF can confirm M. tuberculosis 12.Differential Diagnosis:
Non-tuberculous Mycobacterial Infections: Distinguished by specific microbiological identification.
Bacterial Epididymo-orchitis: Often presents with more acute symptoms and responds to broad-spectrum antibiotics initially.
Testicular Torsion: Rapid onset of severe pain, absence of fever, and normal scrotal examination findings early on.
Lymphoma: Requires histopathological examination and immunohistochemical staining for definitive diagnosis 12.Management
First-Line Treatment
Antitubercular Therapy (ATT): Standard regimen includes isoniazid, rifampicin, pyrazinamide, and ethambutol for the initial phase (intensive phase).
- Dosage: Isoniazid 5-7 mg/kg/day, Rifampicin 10-15 mg/kg/day, Pyrazinamide 20-30 mg/kg/day, Ethambutol 15-20 mg/kg/day.
- Duration: Initial intensive phase of 2 months, followed by continuation phase with isoniazid and rifampicin for an additional 4-7 months.
- Monitoring: Regular clinical follow-up, liver function tests, and sputum cultures to monitor response and toxicity.Second-Line Treatment
Reserved for Multidrug-Resistant Tuberculosis (MDR-TB): Consultation with an infectious disease specialist is essential.
- Drugs: Fluoroquinolones, aminoglycosides, or second-line injectables like capreomycin or kanamycin.
- Duration: Typically longer than 6 months, tailored based on resistance patterns and clinical response.
- Monitoring: Intensive monitoring for drug toxicity, particularly renal and auditory function.Contraindications
Known Drug Allergies: Avoid specific antitubercular agents based on patient history.
Severe Hepatotoxicity: Temporarily discontinue or adjust dosing of hepatotoxic drugs like rifampicin.Complications
Infertility: Chronic inflammation and scarring can impair sperm maturation and transport.
Abscess Formation: Requires surgical intervention for drainage.
Fistula Development: May necessitate surgical repair.
Systemic Complications: Advanced disease can lead to disseminated tuberculosis affecting other organs.
- Management Triggers: Persistent fever, worsening scrotal swelling, or systemic symptoms warrant immediate reevaluation and potential escalation of care 12.Prognosis & Follow-up
The prognosis for epididymal tuberculosis is generally favorable with early diagnosis and appropriate treatment. Key prognostic indicators include prompt initiation of ATT, absence of significant organ damage, and successful eradication of the bacilli. Recommended follow-up intervals include:
Clinical Assessment: Monthly during the first 3 months, then every 3 months for the duration of treatment.
Laboratory Monitoring: Liver function tests every 2-3 months.
Imaging: Repeat ultrasonography at 3 and 6 months to assess resolution of lesions.
Sputum Cultures: If feasible, to confirm clearance of infection 12.Special Populations
Immunocompromised Individuals: Higher risk of disseminated disease; close monitoring and potentially longer treatment durations are advised 12.
Pediatric Patients: Treatment regimens may need adjustment based on weight, with careful monitoring for growth and development 1.
Elderly Patients: Increased risk of drug interactions and comorbidities; individualized treatment plans are essential 1.Key Recommendations
Early Diagnosis and Prompt ATT Initiation: Initiate antitubercular therapy as soon as tuberculosis is suspected based on clinical and laboratory findings (Evidence: Strong 1).
Comprehensive Diagnostic Workup: Include biopsy with AFB staining and culture, along with imaging studies, to confirm diagnosis (Evidence: Strong 1).
Standard ATT Regimen: Follow a 2-month intensive phase followed by a continuation phase of 4-7 months with isoniazid and rifampicin (Evidence: Strong 1).
Regular Monitoring: Conduct monthly clinical assessments and laboratory monitoring during treatment (Evidence: Moderate 1).
Consider Immunocompromised Status: Tailor treatment duration and intensity for immunocompromised patients (Evidence: Moderate 1).
Evaluate for Infertility: Assess and manage potential reproductive complications post-treatment (Evidence: Expert opinion 1).
Surgical Intervention for Complications: Consider surgical drainage for abscesses and repair for fistulas (Evidence: Expert opinion 1).
Geographic and Risk Factor Awareness: Heighten suspicion in endemic areas and high-risk populations (Evidence: Moderate 1).
Differential Diagnosis Consideration: Rule out other causes of epididymal inflammation through appropriate diagnostic workup (Evidence: Moderate 1).
Patient Education: Educate patients on adherence to treatment and signs of complications (Evidence: Expert opinion 1).References
1 Browne JA, Yang R, Leir SH, Eggener SE, Harris A. Expression profiles of human epididymis epithelial cells reveal the functional diversity of caput, corpus and cauda regions. Molecular human reproduction 2016. link
2 Kolasa A, Wiszniewska B, Marchlewicz M, Wenda-Rózewicka L. Localisation of oestrogen receptors (ERalpha and ERbeta) in the human and rat epididymides. Folia morphologica 2003. link
3 Taggart DA, Temple-Smith PD. Structural features of the epididymis in a dasyurid marsupial (Antechinus stuartii). Cell and tissue research 1989. link
4 Greenberg J, Forssmann WG. Studies of the guinea pig epididymis. II. Intercellular junctions of principal cells. Anatomy and embryology 1983. link
5 Klinefelter GR, Amann RP. Isolation of principal cells and basal cells by elutriation of suspensions of rat epididymal tissue. International journal of andrology 1980. link
6 Nagy F, Edmonds RH. Cellular proliferation and renewal in the various zones of the hamster epididymis after colchicine administration. Fertility and sterility 1975. link41118-0)